dehydrocostus lactone has been researched along with Angiogenesis, Pathologic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, J; Mao, H; Sheng, W; Wang, C; Yang, N; Zhang, Z | 1 |
| Chang, YL; Lee, KH; Pan, SL; Peng, CY; Teng, CM; Tsai, AC; Wang, CY | 1 |
2 other study(ies) available for dehydrocostus lactone and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Dehydrocostus Lactone Enhances Chemotherapeutic Potential of Doxorubicin in Lung Cancer by Inducing Cell Death and Limiting Metastasis.
Topics: A549 Cells; Angiogenesis Inhibitors; Animals; Apoptosis; Cell Death; Cell Movement; Cell Proliferation; Doxorubicin; Female; Humans; Lactones; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neovascularization, Pathologic; Sesquiterpenes | 2018 |
Dehydrocostuslactone suppresses angiogenesis in vitro and in vivo through inhibition of Akt/GSK-3β and mTOR signaling pathways.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cells, Cultured; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Lactones; Mice; Neovascularization, Pathologic; Proto-Oncogene Proteins c-akt; Sesquiterpenes; Signal Transduction; TOR Serine-Threonine Kinases | 2012 |